PT1729730E - Forma de dosagem resistente às violações que compreende um adsorvente e um agente adverso - Google Patents

Forma de dosagem resistente às violações que compreende um adsorvente e um agente adverso Download PDF

Info

Publication number
PT1729730E
PT1729730E PT05733184T PT05733184T PT1729730E PT 1729730 E PT1729730 E PT 1729730E PT 05733184 T PT05733184 T PT 05733184T PT 05733184 T PT05733184 T PT 05733184T PT 1729730 E PT1729730 E PT 1729730E
Authority
PT
Portugal
Prior art keywords
adsorbent
dosage form
tamper resistant
adverse agent
resistant dosage
Prior art date
Application number
PT05733184T
Other languages
English (en)
Inventor
Osvaldo Abreu
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US55830104P priority Critical
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of PT1729730E publication Critical patent/PT1729730E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/44Elemental carbon, e.g. charcoal, carbon black
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/47Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0031Rectum, anus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5015Organic compounds, e.g. fats, sugars
PT05733184T 2004-03-30 2005-03-23 Forma de dosagem resistente às violações que compreende um adsorvente e um agente adverso PT1729730E (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US55830104P true 2004-03-30 2004-03-30

Publications (1)

Publication Number Publication Date
PT1729730E true PT1729730E (pt) 2009-04-06

Family

ID=34979862

Family Applications (1)

Application Number Title Priority Date Filing Date
PT05733184T PT1729730E (pt) 2004-03-30 2005-03-23 Forma de dosagem resistente às violações que compreende um adsorvente e um agente adverso

Country Status (24)

Country Link
US (3) US8298579B2 (pt)
EP (1) EP1729730B1 (pt)
JP (2) JP2007530684A (pt)
KR (2) KR101053558B1 (pt)
CN (1) CN1938004B (pt)
AT (1) AT419836T (pt)
AU (1) AU2005231146B2 (pt)
BR (1) BRPI0508769A (pt)
CA (1) CA2557839C (pt)
CY (1) CY1108947T1 (pt)
DE (1) DE602005012244D1 (pt)
DK (1) DK1729730T3 (pt)
ES (1) ES2321012T3 (pt)
HR (1) HRP20090203T1 (pt)
IL (1) IL178175A (pt)
MX (1) MXPA06011122A (pt)
NO (1) NO20064924L (pt)
NZ (1) NZ549479A (pt)
PL (1) PL1729730T3 (pt)
PT (1) PT1729730E (pt)
RS (1) RS50817B (pt)
SI (1) SI1729730T1 (pt)
WO (1) WO2005097075A2 (pt)
ZA (1) ZA200607224B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60238756D1 (de) * 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
WO2003013433A2 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
NZ549479A (en) 2004-03-30 2010-06-25 Euro Celtique Sa Tamper resistant dosage form comprising an adsorbent and an adverse agent
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CA2673837C (en) * 2007-01-05 2015-11-24 Acelrx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
WO2007112581A1 (en) 2006-04-03 2007-10-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US20140010860A1 (en) * 2006-05-12 2014-01-09 Isa Odidi Abuse and alcohol resistant drug composition
CN101969930A (zh) 2007-12-17 2011-02-09 莱博法姆公司;莱博法姆欧洲有限公司;莱博法姆(巴巴多斯)有限公司 防滥用控制释放制剂
US8460640B2 (en) * 2008-12-12 2013-06-11 Paladin Labs, Inc. Narcotic drug formulations with decreased abuse potential
US8486449B2 (en) 2008-12-16 2013-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation
CN102697660B (zh) * 2012-06-04 2014-02-12 贵州景峰注射剂有限公司 一种去除微丸丸间静电的方法
WO2014022541A1 (en) * 2012-08-01 2014-02-06 Acura Pharmaceuticals, Inc. Stabilization of one-pot methamphetamine synthesis systems
WO2014197137A1 (en) * 2013-04-29 2014-12-11 Howard Brooks-Korn Diversion-resistant formulation
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
US20160243107A1 (en) * 2013-12-23 2016-08-25 Purdue Pharma L.P. Opioid Antagonist Formulations
US20160317530A1 (en) * 2013-12-31 2016-11-03 Kashiv Pharma, Llc Abuse-resistant drug formulations
JP2018511355A (ja) 2015-01-28 2018-04-26 クロノ セラピューティクス インコーポレイテッドChrono Therapeutics Inc. 薬剤送達方法及びシステム
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US20190358221A1 (en) * 2017-01-13 2019-11-28 Kashiv Biosciences, Llc Opioid agonist / antagonist combination dosage forms
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3493657A (en) * 1961-03-14 1970-02-03 Mozes Juda Lewenstein Therapeutic compositions of n-allyl-14-hydroxy - dihydronormorphinane and morphine
US3642986A (en) * 1970-04-01 1972-02-15 William Arthur Welch Aspirin-charcoal compositions
US3773955A (en) * 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US3966940A (en) * 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
US4761284A (en) * 1977-12-27 1988-08-02 Kureha Kagaku Kogy Kabushiki Kaisha Antidote including activated carbon particles
JPS5627494B2 (pt) * 1978-05-24 1981-06-25
JPS6346723B2 (pt) * 1979-09-27 1988-09-19 Japan Atomic Energy Res Inst
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
EP0129893B1 (en) * 1983-06-28 1991-09-04 Takeda Chemical Industries, Ltd. Ground mixture
JPH056531B2 (pt) * 1983-06-28 1993-01-26 Takeda Chemical Industries Ltd
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4673565A (en) * 1985-05-03 1987-06-16 E. I. Du Pont De Nemours And Company Pharmaceutical compositions containing hollow fine tubular drug delivery systems
US4594249A (en) * 1985-06-14 1986-06-10 21St Century Marketing, Inc. Method of altering intoxicating effects of alcohol
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4970075A (en) * 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
DE3812567A1 (de) * 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
DE3830353A1 (de) * 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
FR2677886B1 (fr) * 1991-06-18 1995-03-31 Adir Comprime matriciel permettant la liberation prolongee d'indapamide apres administration par voie orale.
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
JPH068220A (ja) 1992-06-23 1994-01-18 Kubota Corp 無機質板の乾式製法における給水方法及びその装置
US5324351A (en) * 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
DE4325465B4 (de) * 1993-07-29 2004-03-04 Jurna, Ilmar, Prof. Dr.med. Orales pharmazeutisches Präparat für die Schmerztherapie
US5492692A (en) * 1993-08-17 1996-02-20 University Of Kentucky Research Foundation Coated products with potent anti-HIV and antimicrobial properties
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5451409A (en) * 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US6007843A (en) * 1995-09-29 1999-12-28 Lam Pharmaceuticals Corp. Sustained release delivery system
DE19539361A1 (de) * 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung
US5846971A (en) * 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
IN183097B (en) * 1997-03-27 1999-09-04 Rajiv Indravadan Dr Modi The process for the preparation of a stable fixed dose pharmaceutical composition of anti infective agent/agents and micro organisms as active ingredients
KR100417490B1 (ko) * 1997-12-22 2004-02-05 유로-셀티크 소시에떼 아노뉨 오피오이드 제형의 남용을 방지하는 방법
EP2266564B1 (en) 1997-12-22 2013-03-13 Euro-Celtique S.A. Pharmaceutical oral dosage form comprising a combination of an opioid agonist and an opioid antagonist
EP1087968A1 (en) * 1998-06-16 2001-04-04 MERCK SHARP & DOHME LTD. Triazolo-pyridine derivatives as ligands for gaba receptors
US6306132B1 (en) * 1999-06-17 2001-10-23 Vivant Medical Modular biopsy and microwave ablation needle delivery apparatus adapted to in situ assembly and method of use
FR2795326B1 (fr) 1999-06-28 2001-08-31 Adir Composition pharmaceutique solide thermoformable a liberation controlee
US6353145B1 (en) * 1999-09-24 2002-03-05 Glenda Church Charcoal poultice
JP2003522146A (ja) * 2000-02-08 2003-07-22 ユーロ−セルティーク,エス.エイ. 外圧に抵抗性の経口オピオイドアゴニスト製剤
DE10006033B4 (de) 2000-02-10 2005-11-10 Professor Dr. Magnus von Knebel Doeberitz Chirurgische Universitätsklinik Sektion für Molekulare Diagnostik und Therapie Immunisierung eines Individuums gegen Carcinome und ihre Vorstufen
AT293439T (de) * 2000-12-07 2005-05-15 Warner Lambert Co Verfahren und system zur gleichmä igen arzneistoffabgabe
KR20030077544A (ko) * 2000-12-22 2003-10-01 아스펜 에어로겔, 인코퍼레이티드 치료 약물을 함유하는 에어로겔 분말
EP1349556A2 (en) * 2001-01-12 2003-10-08 Innovation Ventures, LLC Activated charcoal based composition and method for reducing hangover symptoms associated with the consumption of alcohol containing beverages
JP2002310357A (ja) * 2001-04-18 2002-10-23 Toray Ind Inc 自在継手および浄水器
DE60216078T2 (de) * 2001-05-11 2007-07-05 Endo Pharmaceuticals Inc. Opioid enthaltende arzneiform gegen missbrauch
DE60238756D1 (de) * 2001-05-11 2011-02-10 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
AU2002323032B2 (en) * 2001-08-06 2005-02-24 Euro-Celtique S.A. Opioid agonist formulations with releasable and sequestered antagonist
WO2003013433A2 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
HU0401195A3 (en) 2001-08-06 2006-11-28 Euro Celtique Sa Compositions to prevent abuse of opioids containing aversive agent and process of their preparation
CA2478558C (en) * 2002-03-14 2012-09-11 Euro-Celtique, S.A. Naltrexone hydrochloride compositions
PT1691892E (pt) 2003-12-09 2007-05-31 Euro Celtique Sa Forma posológica co-extrusada inviolável que contém um componente activo e um componente de acção contrária e um processo para a sua fabricação
NZ549479A (en) 2004-03-30 2010-06-25 Euro Celtique Sa Tamper resistant dosage form comprising an adsorbent and an adverse agent
US20100303935A1 (en) * 2009-05-29 2010-12-02 Squires Meryl J Medicinal Composition

Also Published As

Publication number Publication date
DK1729730T3 (da) 2009-03-23
SI1729730T1 (sl) 2009-06-30
EP1729730B1 (en) 2009-01-07
IL178175A (en) 2010-05-17
EP1729730A2 (en) 2006-12-13
CA2557839C (en) 2011-05-10
KR20060135043A (ko) 2006-12-28
KR100963914B1 (ko) 2010-06-17
KR20080095309A (ko) 2008-10-28
AU2005231146A1 (en) 2005-10-20
ES2321012T3 (es) 2009-06-01
CN1938004A (zh) 2007-03-28
US9795681B2 (en) 2017-10-24
US20140256764A1 (en) 2014-09-11
MXPA06011122A (es) 2007-03-21
AT419836T (de) 2009-01-15
WO2005097075A2 (en) 2005-10-20
HRP20090203T1 (xx) 2009-05-31
BRPI0508769A (pt) 2007-08-28
CY1108947T1 (xx) 2014-07-02
KR101053558B1 (ko) 2011-08-03
US20070207089A1 (en) 2007-09-06
CN1938004B (zh) 2011-12-21
NZ549479A (en) 2010-06-25
JP2011093927A (ja) 2011-05-12
NO20064924L (no) 2006-12-21
WO2005097075A3 (en) 2006-08-03
AU2005231146B2 (en) 2008-12-11
CA2557839A1 (en) 2005-10-20
US20130017255A1 (en) 2013-01-17
DE602005012244D1 (de) 2009-02-26
IL178175D0 (en) 2006-12-31
JP2007530684A (ja) 2007-11-01
US8298579B2 (en) 2012-10-30
PL1729730T3 (pl) 2009-06-30
ZA200607224B (en) 2008-04-30
RS50817B (xx) 2010-08-31

Similar Documents

Publication Publication Date Title
TWI369981B (en) Hmb compositions and uses thereof
EG24839A (en) Inhaler
GB2411554B (en) Multi-rate security
DK1716145T3 (da) Dihydrotetrabenaziner og farmaceutiske præparater indeholdende disse
GB2443569B (en) Security device
IL183458D0 (en) Anti-il-1r1 single domain antibodies and therapeutic uses
PL3175884T3 (pl) Zintegrowana resuscytacja
EP2080242A4 (en) Toposcopic access and delivery devices
IL177325D0 (en) Permanent resist composition, cured product thereof, and use thereof
HK1119989A1 (en) Game device
DK1729730T3 (da) Manipulationssikker doseringsform, der omfatter et adsorberende stof og et kontramiddel
IL181301D0 (en) Cyclopamine analogues, pharmaceutical compositions comprising them and uses thereof
EP1761296A4 (en) Flange occlusion devices and methods
EP1934853A4 (en) Progressive game and processing system thereof
EP1742627A4 (en) Pde4b inhibitors and uses therefor
EP1920216A4 (en) Location signposting and orientation
AU158576S (en) Inhaler
EP1814633A4 (en) Respiratory mask seal and mask using same
GB0525443D0 (en) Superconduction-technology device
EP1581188A4 (en) Pharmaceutical safety dosage forms
GB0407972D0 (en) Tamper respondent covering
PT1765793E (pt) Nacetrapib e outros inibidores de cetp
EP1887067A4 (en) Phosphor and use thereof
HK1110811A1 (en) Medicine injection devices and methods
SG10201507902UA (en) Solid pharmaceutical dosage form